Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma.
Hiroki IshiharaYuki NemotoHidekazu TachibanaHironori FukudaKazuhiko YoshidaHirohito KobayashiJunpei IizukaYasunobu HashimotoTsunenori KondoToshio TakagiPublished in: Japanese journal of clinical oncology (2023)
Cabozantinib in Japanese patients with advanced renal cell carcinoma who failed immune checkpoint inhibitors was efficacious and had a manageable safety profile. These results appear to be similar to those of previous clinical trials.